What is Correlia Biosystems?
Correlia Biosystems specializes in microscale analysis for protein measurement, offering the PIXI platform, a next-generation automated immunoassay system. Their technology enables highly accurate and reproducible protein quantification with minimal sample input and rapid turnaround times. Targeted towards biopharmaceutical analysis, cell and gene therapy, and synthetic biology, they provide both off-the-shelf and custom assay solutions. Designed in collaboration with leading pharmaceutical companies, their products aim to enhance scientific discovery in the proteomics field. The company's Series A financing round in November 2020 marked a significant step in its growth trajectory, positioning it for further development and market penetration in the advanced life sciences sector.
How much funding has Correlia Biosystems raised?
Correlia Biosystems has raised a total of $7M across 1 funding round:
Series A
$7M
Series A (2020): $7M with participation from Cota Capital and Neotribe Ventures
Key Investors in Correlia Biosystems
Cota Capital
Cota Capital is an investment firm that focuses on early-stage technology companies addressing innovative challenges in the enterprise sector. They combine financial investment with deep operational expertise and industry insights to empower founders in building transformative businesses.
Neotribe Ventures
Neotribe Ventures is a Silicon Valley-based venture capital firm that identifies and funds entrepreneurs developing breakthrough technologies with the potential to create transformative market movements. The firm actively collaborates with its portfolio companies, leveraging extensive experience and a broad network to provide strategic guidance and operational support.
What's next for Correlia Biosystems?
With its recent major strategic investment and a history of enterprise-level capital raises, Correlia Biosystems is poised for accelerated growth. The company's focus on enhancing scientific discovery in proteomics, particularly within biopharmaceutical analysis and cell/gene therapy, aligns with current industry demands for more efficient and accurate protein quantification. Future developments will likely involve scaling production of the PIXI platform, expanding assay solutions, and forging deeper collaborations with key players in the life sciences and biotechnology industries. This strategic financing will be instrumental in achieving these objectives and solidifying Correlia Biosystems' position as an innovator in automated immunoassay systems.
See full Correlia Biosystems company page
